10,000 Shares in Astrana Health, Inc. (NASDAQ:ASTH) Purchased by Truist Financial Corp

Truist Financial Corp bought a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,000 shares of the company's stock, valued at approximately $315,000.

Other large investors have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC acquired a new stake in Astrana Health during the third quarter worth approximately $35,000. KBC Group NV bought a new stake in Astrana Health in the 3rd quarter valued at about $70,000. Quarry LP bought a new stake in Astrana Health in the 3rd quarter valued at about $77,000. Quest Partners LLC acquired a new position in Astrana Health during the 3rd quarter worth approximately $133,000. Finally, Paloma Partners Management Co bought a new position in Astrana Health in the third quarter worth approximately $220,000. Institutional investors and hedge funds own 52.77% of the company's stock.

Astrana Health Stock Up 8.0 %

Astrana Health stock traded up $2.17 during midday trading on Friday, hitting $29.38. 513,813 shares of the stock were exchanged, compared to its average volume of 246,110. Astrana Health, Inc. has a 52-week low of $23.12 and a 52-week high of $63.20. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of 22.60, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. The business's 50-day moving average price is $34.25 and its 200-day moving average price is $43.80. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.

Remove Ads

Astrana Health (NASDAQ:ASTH - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The firm had revenue of $665.21 million for the quarter, compared to analysts' expectations of $617.24 million. On average, research analysts expect that Astrana Health, Inc. will post 1.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ASTH shares. Truist Financial decreased their price objective on Astrana Health from $59.00 to $50.00 and set a "buy" rating for the company in a report on Monday, January 13th. Bank of America lowered their price objective on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Macquarie raised shares of Astrana Health to a "hold" rating in a research note on Monday, December 16th. Robert W. Baird decreased their target price on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. Finally, Stifel Nicolaus lowered their target price on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Astrana Health currently has a consensus rating of "Moderate Buy" and an average target price of $56.83.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.